6 GLP-1 Drug Combinations Being Studied for Weight Loss in 2026

The first generation of GLP-1 drugs proved that pharmacological weight loss of 15 to 22 percent was possible. The next generation aims to push that number to 25 to 30 percent while addressing the key limitation of current drugs: muscle loss. Pharmaceutical companies are investing billions in combination therapies that target obesity through multiple mechanisms simultaneously. Here are six approaches being studied right now.

CagriSema: Semaglutide Plus Amylin Analog Cagrilintide

Novo Nordisk’s CagriSema combines semaglutide (the active ingredient in Wegovy) with cagrilintide, an amylin receptor agonist. Amylin is a hormone co-released with insulin that promotes satiety and slows gastric emptying. Phase 3 trial results published in late 2024 showed that CagriSema produced weight loss of approximately 22 to 25 percent, exceeding semaglutide alone. The dual mechanism provides stronger appetite suppression through two different satiety pathways. Novo Nordisk has indicated potential FDA approval timelines in 2026, which would make this one of the first next-generation obesity combination therapies available.

Why it matters for your metabolic age: Greater weight loss combined with improved blood sugar control from dual hormone targeting could produce larger metabolic age reductions than current single-drug therapies.

Survodutide: GLP-1 Plus Glucagon Receptor Agonist

Boehringer Ingelheim’s survodutide combines GLP-1 receptor agonism with glucagon receptor agonism. This is a counterintuitive approach because glucagon typically raises blood sugar, but in combination with GLP-1, the glucagon component increases energy expenditure and promotes fat oxidation while the GLP-1 component controls appetite and blood sugar. Phase 2 trials published in The Lancet showed weight loss of up to 19 percent at 46 weeks. Importantly, the glucagon component appears to increase resting metabolic rate, which could help address the metabolic adaptation problem that plagues all current weight loss approaches. Phase 3 trials are ongoing in 2026.

Retatrutide: Triple-Hormone Receptor Agonist

Eli Lilly’s retatrutide targets three receptors simultaneously: GLP-1, GIP, and glucagon. Phase 2 trial results published in the New England Journal of Medicine showed unprecedented weight loss of up to 24 percent at 48 weeks, with some participants losing over 30 percent. The triple mechanism provides appetite suppression (GLP-1 and GIP), increased energy expenditure (glucagon), and enhanced insulin sensitivity (GIP). Phase 3 trials are progressing, with results expected in late 2026. If the phase 3 data confirms the phase 2 results, retatrutide could become the most effective obesity drug ever developed.

Why it matters for your metabolic age: The glucagon component’s effect on energy expenditure may preserve metabolic rate during weight loss, potentially producing metabolic age improvements that are more sustainable long-term.

Bimagrumab Plus Semaglutide: Targeting Muscle Preservation

Bimagrumab is an activin receptor antibody that promotes muscle growth and inhibits fat storage. A study published in JAMA Network Open found that bimagrumab combined with semaglutide produced equivalent total weight loss to semaglutide alone, but with dramatically different body composition. The combination group lost more fat and actually gained muscle mass during treatment. This directly addresses the biggest limitation of current GLP-1 therapy. If further trials confirm these results, adding bimagrumab could transform GLP-1 treatment from a blunt weight loss tool into a precision body composition therapy. Phase 2 trials are ongoing with expansion planned for 2026.

Orforglipron Plus Lifestyle Intervention: The Oral GLP-1 Approach

Most current GLP-1 drugs require weekly injections, which is a barrier for many patients. Orforglipron is an oral GLP-1 receptor agonist from Eli Lilly that can be taken as a daily pill. Phase 3 trial results showed weight loss of approximately 12 to 14 percent, somewhat less than injectable options but delivered in a more accessible format. The combination being studied pairs orforglipron with structured lifestyle interventions including exercise programming and dietary counseling. Early data suggests that this combined approach may narrow the gap with injectable drugs while being more practical for widespread use.

Why it matters for your metabolic age: An oral option with structured lifestyle support could bring effective weight loss treatment to millions more people, enabling broader metabolic age improvements across the population.

Pemvidutide: GLP-1 Plus Glucagon With Liver Fat Focus

Altimmune’s pemvidutide is a dual GLP-1 and glucagon receptor agonist with a particularly strong effect on liver fat. Phase 2 data showed weight loss of approximately 15 percent along with significant reductions in liver fat and improvements in markers of non-alcoholic fatty liver disease (NAFLD). Given that NAFLD affects an estimated 25 to 30 percent of adults globally and is closely linked to metabolic syndrome, a drug that addresses both obesity and liver disease simultaneously has enormous clinical potential. The liver fat reduction may also improve insulin sensitivity beyond what weight loss alone would achieve. Phase 2b trials are completing in 2026.

Why it matters for your metabolic age: Liver fat reduction improves insulin sensitivity and blood sugar regulation more powerfully than subcutaneous fat loss alone, potentially producing outsized metabolic age improvements.

Track Your Metabolic Health Regardless of Which Treatment You Choose

The obesity treatment space is evolving rapidly. Whatever approach you use, tracking your metabolic health gives you the data to evaluate what is actually working. Penlago’s free MetaAge calculator uses blood pressure, blood sugar, BMI, and age to produce your metabolic age in 60 seconds. It is a simple way to see the metabolic impact of any treatment or lifestyle change.

Find out your metabolic age in 60 seconds – free.